Does elevated Lp-PLA2 activity reflect plaque inflammation?

Lp-PLA₂ is a lipoprotein-associated enzyme with biologically credible involvement in atherosclerotic tissue, but its circulating activity is best viewed as a modest risk marker rather than a specific blood measure of plaque inflammation.

Clinical and prognostic evidence

• Higher circulating Lp-PLA₂ activity is associated with greater cardiovascular event risk in prospective data. Across 11 cohorts (32,075 participants), each 1-SD increase was associated with a 12% higher adjusted cardiovascular-event hazard (HR 1.12, 95% CI 1.09–1.21).
• In an individual-participant meta-analysis of 32 prospective studies (79,036 people), activity was associated with coronary heart disease (RR 1.10 per SD, 95% CI 1.05–1.16) and vascular death (RR 1.16, 95% CI 1.09–1.24). The ischemic-stroke estimate was smaller and statistically compatible with no association (RR 1.08, 95% CI 0.97–1.20).
• In a 146-patient coronary angiography/intravascular-ultrasound cohort, higher activity was independently associated with plaque rupture after adjustment for conventional risk factors, hs-CRP, and IVUS measures. This supports an association with rupture-prone plaque, not proven causation or a validated prospective prediction tool.

Mechanistic interpretation

• Within human plaques, Lp-PLA₂ is enriched in macrophage-rich, lipid-rich necrotic-core regions and associates with inflammatory cytokines. It hydrolyzes oxidized phospholipids, generating lysophosphatidylcholine and oxidized fatty acids—products with plausible pro-inflammatory vascular effects.
• However, plasma Lp-PLA₂ mass and activity did not correlate with carotid-plaque Lp-PLA₂. Because circulating activity is influenced by ApoB-containing lipoproteins, including LDL, an elevated result cannot reliably be interpreted as inflammation within an individual’s plaque.

Clinical implications

• Lp-PLA₂ adds little to conventional risk reclassification and is not a stand-alone determinant of cardiovascular risk or a routinely useful screening test.

Bottom line

• Elevated Lp-PLA₂ activity is associated with modestly higher cardiovascular risk and with plaque vulnerability, but it does not specifically reflect local plaque inflammation.